IMPORTANT ANTHERA PHARMACEUTICALS, INC. INVESTOR A

NEW YORK, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class has been commenced in the United States District Court for  the Northern  District  of   California  on  behalf   of  purchasers  of   Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ) (“Anthera” or the “Company”) common  stock during the period between February 10,  2015 and December 27, 2016,  inclusive (the “Class Period”). 

Investors who have incurred losses in shares of Anthera Pharmaceuticals, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you  have  purchased  shares of  Anthera Pharmaceuticals, Inc. within the class period and would like to assist with the litigation process, you may, no later than April 17,  2017 , request that the Court appoint you lead plaintiff of the proposed class.

The filed complaint accuses the defendants of failing to disclose during the Class Period that patients were not improving in the CHABLIS-SC1 clinical trial and there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

Following a November 10, 2016 press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systematic lupus  erythematosus  failed  to  meet  its  primary endpoint, and a December 27, 2016  press release announcing that the  Solution Study in cystic fibrosis patients with exocrine pancreatic insufficiency missed the Coefficient of Fat Absorption non-inferiority margin of the primary modified Intent to Treat, the value of Anthera shares declined significantly.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com , or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook . ##

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com Tel: (800) 575-0735 or (212) 545-4774